Breast cancer
Conditions
Interventions
Experimental group:Pyrotinib, Capecitabine or Vinorelbine or Eribulin, combined with Trastuzumab
Sponsors
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Patients with stage II (ct3n0m0) - III breast cancer confirmed by pathology; 2. Female, age >= 18 and <= 70 years; 3. Subjects with ECoG score of 0 or 1 were evaluated for tolerance to follow-up treatment; 4. Subjects who had received neoadjuvant regimen containing trastuzumab combined with patuzumab for at least 2 cycles and were assessed as SD (0-20% increase) or PD according to RECIST 1.1; 5. The volunteers signed informed consent, had good compliance and were willing to cooperate with the follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with severe cardiovascular and cerebrovascular or mental diseases; 2. Pregnant and lactating women, women with fertility and positive baseline pregnancy test, or women of childbearing age who are not willing to take effective contraceptive measures during the whole trial period; 3. The patients who can't swallow, chronic diarrhea and intestinal obstruction have many factors that affect the drug taking and absorption; 4. Patients who had used the research drugs of other clinical trials in the first 4 weeks before enrollment; 5. Patients receiving any other anti-tumor therapy at the same time; 6. Patients with bilateral breast cancer and inflammatory breast cancer; 7. According to the judgment of the researcher, there are patients with accompanying diseases that seriously endanger the safety of patients or affect the completion of the study (including but not limited to severe hypertension, severe diabetes, etc., which cannot be controlled by drugs); 8. The researcher thinks that the patient is not suitable for any other situation of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic complete response; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Disease free survival; | — |
Countries
China
Contacts
Public ContactQianjun Chen, Rui Xu
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed